Filtreler
A controversial new approach to address hematological parameters in Hashimoto's thyroiditis

Arpaci D. | Gürol G. | Ergenc H. | Yazar H. | Tocoglu A.G. | Ciftci I.H. | Tamer A.

Article | 2016 | Clinical Laboratory62 ( 7 ) , pp.1225 - 1231

Background: Hashimoto's thyroiditis (HT) is a common autoimmune disorder. Genetic, environmental, and immunological factors all play a role in the pathogenesis of HT, but the effects of lymphocytes and platelets on the pathophysiology of HT are still unknown. In this study, we evaluated the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) in HT groups and HT subgroups with low cardiovascular risks. Methods: This study included 92 patients with HT and 38 control subjects. Among the HT patients, three subgroups were formed according to thyroid function: overt (n = 12), subclinica . . .l (n = 38), and euthyroid (normally functioning thyroid; n = 42). Results: Age and gender distributions were similar between the patient and control groups. Body mass index was higher in the patient group than in the control group. The C reactive protein level was higher in patients than controls (p = 0.064). The thyroid stimulating hormone (TSH) level was higher and the mean free thyroxine level lower in the patient group than in the control group (p < 0.05). There were no differences between the groups with regard to leukocytes, neutrophils, platelets, or MPV (p > 0.05). The NLR and PLR were significantly different in one subgroup of HT patients relative to healthy subjects (p < 0.05). However, we did not find any statistical differences in the MPV among the three subgroups (p = 0.547). A positive correlation was found among the NLR, anti-thyroglobulin (TG) antibodies, and anti-thyroid peroxidase (TPO) antibodies (p < 0.01), although there was a negative correlation between the PLR, TSH, anti-TPO, and anti-TG (p < 0.001). Conclusions: A single marker or panel of biomarkers is not a consistent indicator of HT, but NLR combined with PLR testing may offer a more reliable diagnosis. © 2016, Verlag Klinisches Labor GmbH. All rights reserved Daha fazlası Daha az

Is Mean Platelet Volume a Reliable Marker to Predict Ischemic Stroke in the Follow-Up of Patients with Carotid Stenosis?

Oz I.I. | Yucel M. | Bilici M. | Şerifo?lu I. | Sayin R. | Ilikhan S.U. | Acikgoz M.

Article | 2016 | Journal of Stroke and Cerebrovascular Diseases25 ( 2 ) , pp.404 - 409

Background The objective of the study is to evaluate the reliability of mean platelet volume (MPV) for predicting ischemic stroke (cerebrovascular event [CVE]) among patients with different degrees of carotid stenosis. Methods Fifty-two patients with CVEs, 136 patients with carotid artery disease (CAD), and 40 healthy volunteers were enrolled in this study. All participants were divided into the following groups according to CAD: absence of stenosis, less than 50% stenosis, 50%-69% stenosis, and 70% or more to total occlusion of the internal carotid artery. For each participant, the parameters of CAD were assessed using ultrasonogra . . .phy. To obtain the values of CRP and MPV and the leukocyte and platelet counts, all samples were processed within 30 minutes after blood collection. Univariate and multivariate analyses were used to evaluate the association between the values of serum C-reactive protein (CRP) and MPV and carotid stenosis. Results In terms of age and gender, there was no statistically significant difference between the groups (P =.094 and P =.428, respectively). However, CRP values in patients with CAD and CVEs were significantly higher than those in the controls (P Daha fazlası Daha az

Renal artery stenosis and mean platelet volume

Sayın M.R. | Yavuz N. | Karabağ T. | Çetiner M.A. | Öz İ.İ. | Güngördük O.A. | Aydın M.

Review | 2016 | Anatolian Journal of Cardiology16 ( 3 ) , pp.197 - 201

Objective: Increased mean platelet volume (MPV) has been reported in various atherosclerotic diseases. The aim of our study was to investigate the relationship between the atherosclerotic renal artery stenosis (ARAS) and various hematological parameters including MPV. Methods: This study was performed with a retrospective review of the angiographic images of patients who underwent renal angiography at Bülent Ecevit University catheter laboratory between January 2004 and December 2009. The patients were trichotomized into three groups based on the presence and severity of renal artery stenosis (RAS). Group 1 included patients with a . . .critical RAS (33 patients; 18 female (F), 15 male (M); mean age 61.6±11.5 years), group 2 consisted of patients with non-critical RAS (26 patients; 15 F, 11 M; mean age 58.1±11.3 years), and group 3 was composed of patients without RAS (69 patients; 38 F, 31 M; mean age 53.5±11.9 years). Demographic data, complete blood count, and biochemical parameters were compared between the groups. Results: Comparison of the hematological parameters revealed that MPV and platelet distribution width were significantly higher in group 1 than in group 2 and 3 (8.96±0.99 fL versus 8.35±0.76 fL, 8.31±0.79 fL, respectively; p=0.001; 16.53±0.58% versus 16.19±0.56%, 16.29±0.53%, respectively; p=0.04). Conclusion: MPV levels are higher in patients with ARAS. Considering both the effect of platelets on atherosclerosis and their close association with other risk factors, MPV level may be an important factor in pathogenesis of ARAS. © 2016 by Turkish Society of Cardiology Daha fazlası Daha az

Plateletcrit in Ocular Pseudoexfoliation Syndrome

Yazgan S. | Celik U. | Kaldirim H. | Ayar O. | Akdemir M.O.

Article | 2016 | Eye and Contact Lens42 ( 5 ) , pp.328 - 332

Purpose: The aim of this study was to compare all platelet markers, especially plateletcrit (PCT, total platelet mass), in patients with and without ocular pseudoexfoliation (PEX) syndrome. Methods: One hundred six patients with ocular PEX syndrome (study group) and 106 individuals without ocular PEX syndrome (control group) were enrolled in this retrospective case-control study. The biochemical/hematological laboratory results of both the study and control groups were analyzed by a clinician blinded to the group assignments. The main outcome measures were the PCT, platelet count (PLT), mean platelet volume (MPV), and platelet distr . . .ibution width (PDW). Results: The mean PCT in the study and control groups were 0.206%±0.520% and 0.171%±0.410%, respectively ( Daha fazlası Daha az

Platelet and mean platelet volume kinetics in adult patients with sepsis

Aydemir H. | Piskin N. | Akduman D. | Kokturk F. | Aktas E.

Article | 2015 | Platelets26 ( 4 ) , pp.331 - 335

The aims of this study were to evaluate the kinetics of platelet counts and mean platelet volume (MPV) in adults with sepsis and to determine whether the responses are infection-specific. This retrospective cohort study included patients admitted to a tertiary-care teaching hospital with microbiologically proven nosocomial sepsis between January 2006 and January 2011. Platelet counts and MPV measurements were examined daily for 5 days after the onset of sepsis. During the study period, 151 of the 214 sepsis episodes were associated with thrombocytopenia. Gram-positive microorganisms were the most frequently isolated. The decrease in . . . platelet counts was statistically significant for the first 3 days of sepsis in Gram-positive septic patients, for 4 days in Gram-negative septic patients and for all 5 days in fungal septic patients ( Daha fazlası Daha az

Assessment of mean platelet volume and its effect on disease control in patients with acromegaly

Arpaci D. | Kuzu F. | Unal M. | Ilikhan S.U. | Buyukuysal M.C. | Bayraktaroglu T.

Article | 2016 | Clinical Laboratory62 ( 11 ) , pp.2167 - 2171

Background: Morbidity and mortality rates due to cardiovascular diseases are more common in acromegalic patients than the healthy population. Platelets play a significant role in both the onset and progression of clotting which then cause the development of atherosclerotic plaques. Increased mean platelet volume (MPV) is an indicator of platelet activation and known as an independent risk factor for atherosclerotic processes. The aim of this study was to compare MPV levels between acromegalic and non-acromegalic patients. Methods: The data of 56 acromegalic patients and 72 controls matched for age, gender, and the presence of diabet . . .es were retrospectively reviewed. Results: MPV levels were found to be higher in acromegalic patients compared to controls (8.82 ± 1.17 fL and 7.74 ± 0.87 fL, respectively, p < 0.001). Acromegalic patients were also classified according to their status of remission (a total of 27 patients were in remission and 29 patients were not in remission). Both age and gender were similar between the groups (p = 0.145 and p = 0.616, respectively). MPV levels at the time of diagnosis and after six months of treatment (p = 0.555 and p = 0.917, respectively) were not statistically significant. Conclusions: Our results suggest that MPV levels are higher in acromegalic patients than the controls until the early stages of treatment, independent of diabetes. Therefore, MPV levels may be an important determinant of acromegalic patients Daha fazlası Daha az

The mean platelet volume and atherogenic index of plasma in nondipper normotensive individuals compared to dippers

Yildiz G. | Hür E. | Özçiçek A. | Candan F. | Kayatas M.

Article | 2013 | Clinical and Experimental Hypertension35 ( 1 ) , pp.35 - 39

Mean platelet volume (MPV) is a determinant of platelet activation. Atherogenic index of plasma (AIP), which is defined as the logarithm of the ratio of plasma level of triglycerides to the level of high-density lipoprotein (HDL)-cholesterol (log[TG/HDL-C]), has recently been used as a marker of atherogenicity. This study included 104 normotensive individuals. Mean platelet volume and AIP were measured in all patients. Nondipper individuals (8.6 ± 0.9 fL, 0.3 ± 0.2) demonstrated higher values of MPV and AIP compared with dippers (7.9 ± 1.1 fL, 0.1 ± 0.2) (P < .001 and < .001, respectively). Mean platelet volume and AIP have a positi . . .ve correlation with insufficient decline in nocturnal blood pressure. © 2013 Informa Healthcare USA, Inc Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms